News

The company plans to make the diagnostic available to physicians and researchers this summer, expanding its portfolio beyond ...
Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to ...
H.U. Group Holdings Inc. and its subsidiary Fujirebio Holdings, Inc., have announced that Fujirebio Diagnostics, Inc. has acquired Plasma Services Group, Inc. (PSG), a ...
Fujirebio Diagnostics’ blood test for Alzheimer’s disease offers a less expensive and less invasive alternative compared to medical imaging and tests of cerebrospinal fluid. But competition ...
(BUSINESS WIRE )--Fujirebio today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company's Lumipulse ® G pTau 217/β-Amyloid 1-42 Plasma Ratio in ...
Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the debilitating neurodegenerative disease. Fujirebio’s Lumipulse G ...
Agappe and Fujirebio Japan are redefining excellence in global diagnostics by delivering cutting-edge CLEIA-based immunoassay analyzers for selected countries as agreed upon.
Fujirebio submitted a regulatory filing with the FDA in September for its test. It is the first commercially available blood-based in vitro diagnostic test for assessing Alzheimer’s in the U.S.
Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...
Quest Diagnostics has signed up to offer a blood test that can help diagnose Alzheimer’s disease, following its FDA clearance earlier this year. | The Lumipulse G blood test measures the ratio between ...